Add to that the Phase 3 FDA trials that lead to that approval:
A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age
Without much research I can quickly see 5,762 reasons why it is best to DYOR outside of HC, which would generally include listening to the ones that have a proven track record in that field, such as our CMO.
Add to that the Phase 3 FDA trials that lead to that approval:A...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.015(9.68%) |
Mkt cap ! $38.41M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 17.0¢ | 15.5¢ | $47.10K | 289.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 23813 | 3 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |